REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (REGISTRY)
This is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers to:
- obtain natural history data on many HD mutation carriers and individuals who are part of an HD family
- relate phenotypical characteristics (genetic modifiers / wet and dry biomarkers)
- expedite identification and recruitment of participants for clinical trials
- develop and validate sensitive and reliable outcome measures for detecting onset and change over the natural course of premanifest and manifest HD which may also be potential outcome measures for use in future clinical trials and clinical care
- plan for future research studies
|Study Design:||Observational Model: Cohort|
|Official Title:||REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|
- Phenotypical characteristics of HD [ Time Frame: 13 years ] [ Designated as safety issue: No ]The goal of the project is to collect longitudinal data on the phenotypical characteristics of HD gene mutation carriers.
Biospecimen Retention: Samples With DNA
- DNA from whole blood
- Lymphoblastoid cell lines
|Study Start Date:||June 2004|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||July 2016 (Final data collection date for primary outcome measure)|
REGISTRY integrates prospectively and systematically collected clinical research data (e.g. phenotypical clinical features, family history, demographical characteristics) with access to biological specimens (e.g. blood, urine) obtained from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g. spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation).
REGISTRY is an open-ended study and eligible subjects are assessed at annual study visits on the phenotypical characteristics of HD regardless of whether they display clinical symptoms and signs of the disease and of individuals who are part of an HD family (irrespective of their mutation carrier status). At each study visit, general clinical, motor function, behavior, cognitive, Health Economics, Quality of Life assessments are administered. In addition, participants are given the option to consent to the donation of biosamples for the purposes of mutation (CAG repeat length) testing and for research to identify biological modifiers and markers of HD. Biological specimens and phenotypical data are made available to qualified scientists whose projects are reviewed and approved by the Scientific and Bioethical Advisory Committee (SBAC) of EHDN. Successful applicants agree to accept the EHDN policies surrounding the use of the data/materials provided and publication of results (see data sharing and publication policies of EHDN, attached). Research projects should aim to advance scientific knowledge towards establishing clinically effective treatments that delay onset and/or slow the progression of the disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01590589
|Contact: Jenny Townhill, Dr.||firstname.lastname@example.org|
|Contact: Katrin Barth||+49 731 email@example.com|
Show 140 Study Locations
|Principal Investigator:||Bernhard Landwehrmeyer, Professor||University Hospital of Ulm / Dept. of Neurology|